Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for Bezisterim (NE3107) in Neurological symptoms associated with long COVID. The expected timing is based on the latest available company guidance and may change.
ADDRESS-LC trial. 5/15/25- Enrolled first patient. Topline data in H1 2026. 01/08/26:- ADDRESS-LC Phase 2 enrolling about 200 patients; topline data now expected Mid-2026. 02/12/26:- ADDRESS-LC baseline characteristics poster at ACP Feb 18, 2026. Topline Ph2 ADDRESS-LC data expected Mid-2026. 05/18/26:- ADDRESS-LC still enrolling about 200; topline Phase 2 data expected Late Summer 2026. 05/26/26:- ADDRESS-LC fully enrolled. Topline Phase 2 data still expected Late Summer 2026.
Verification
Confirm timing and program details against the company announcement or filing.